Enterostatin (VPDPR) and Its Peptide Fragment DPR Reduce Serum Cholesterol Levels after Oral Administration in Mice

2003 ◽  
Vol 67 (7) ◽  
pp. 1620-1622 ◽  
Author(s):  
Yasuyuki TAKENAKA ◽  
Futoshi NAKAMURA ◽  
Taichi YAMAMOTO ◽  
Masaaki YOSHIKAWA
Keyword(s):  
Oral Administration ◽  
Serum Cholesterol ◽  
Peptide Fragment ◽  
Cholesterol Levels ◽  
Reduce Serum Cholesterol

scholarly journals Pea Protein Reduce Serum Cholesterol Levels in Hypercholesterolemia Hamsters by Modulating Compositions Of Gut Microbiota And Metabolites

2021 ◽  
Author(s):  
Li-Tao Tong ◽  
Tianzhen Xiao ◽  
Lili Wang ◽  
Cong Lu ◽  
Liya Liu ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Serum Cholesterol ◽  
Pea Protein ◽  
Cholesterol Levels ◽  
Reduce Serum Cholesterol

Cholesterol Reduction among Volunteers in a Health Promotion Project

1988 ◽  
Vol 2 (4) ◽  
pp. 5-12 ◽  
Author(s):  
Steven P. Singleton ◽  
Anne Victoria Neale ◽  
Richard O. Scott ◽  
Joseph W. Hess
Keyword(s):  
Health Promotion ◽  
Serum Cholesterol ◽  
Intervention Strategy ◽  
Heart Association ◽  
High Serum ◽  
Dietary Guidelines ◽  
Health Promotion Program ◽  
High Serum Cholesterol ◽  
Cholesterol Levels ◽  
Reduce Serum Cholesterol

Behavioral contracting was used with moderate success as a primary intervention strategy in an urban clinic-based health promotion program designed to reduce serum cholesterol. Of the 223 adults screened, 144 had high serum cholesterol. One hundred and eighteen attended an interpretation/education session, and 51 participants agreed to sign a behavioral contract. Among those who signed contracts, adherence to American Heart Association dietary guidelines was significantly related to serum cholesterol changes. Eleven of the 46 adults who returned for the six-month clinical assessment reduced their cholesterol levels to recommended levels.

scholarly journals Analysis of Serum Cholesterol, Statins and Atherosclerotic Plaque in Ruptured and Unruptured Intracranial Aneurysm

2022 ◽  
Author(s):  
Leonardo Zumerkorn Pipek ◽  
Nícollas Nunes Rabelo ◽  
Henrique Zumerkorn Pipek ◽  
Joao Paulo Mota Telles ◽  
Natalia Camargo Barbat ◽  
...  
Keyword(s):  
Intracranial Aneurysm ◽  
Atherosclerotic Plaque ◽  
Serum Cholesterol ◽  
Linear Regression Models ◽  
High Cholesterol ◽  
Cholesterol Levels ◽  
Reduce Serum Cholesterol ◽  
Radiological Images ◽  
The Impact

Abstract Introduction Intracranial aneurysm (IA) is a major healthcare concern. The use of statin to reduce serum cholesterol has shown evidence to reduce cardiovascular risk in various diseases, but the impact on IA has not been described. This study aims to determine whether statin use, and serum cholesterol levels interfere with outcomes after IA event. Methods A cohort of patients with IA was analyzed. Patients social and demographics data were collected. Modified Rankin scale (mRS) score after 6 months of follow-up was the endpoint. The data regarding statins use, presence or not of atherosclerotic plaque in radiological images and serum cholesterol of 35 patients were included in our study. Linear regression models were used to determine the influence of those 6 variables in the clinical outcome. Results The prevalence of atherosclerotic plaque, high cholesterol and use of statins was 34.3%, 48.5%, and 14.2%, respectively. Statins and serum cholesterol did not impact the overall outcome, measured by mRS after 6 months (p > 0.05), but did show different tendencies when separated by IA rupture status. Serum cholesterol shows an important association with rupture of aneurysm (p = 0.0382). High cholesterol and use of statins show a tendency for worse outcome with ruptured aneurysm, and the opposite is true for unruptured aneurysm. The presence of atherosclerotic plaques was not related with worse outcomes. Conclusions Multiple and opposite mechanisms might be involved in the pathophysiology of IA. Ruptured aneurysms are associated with higher levels of serum cholesterol. Serum cholesterol and statins use were not correlated with worse outcomes, but further studies are important to clarify these relationships.

scholarly journals Tea Catechins Reduce Serum Cholesterol Levels in Mild and Borderline Hypercholesterolemia Patients

2003 ◽  
Vol 33 (3) ◽  
pp. 101-111 ◽  
Author(s):  
Osami Kajimoto ◽  
Yoshitaka Kajimoto ◽  
Mitsuharu Yabune ◽  
Ayumu Nozawa ◽  
Kozo Nagata ◽  
...  
Keyword(s):  
Serum Cholesterol ◽  
Tea Catechins ◽  
Cholesterol Levels ◽  
Reduce Serum Cholesterol

Cost-Effectiveness of Populationwide Educational Approaches to Reduce Serum Cholesterol Levels

Circulation ◽  
1997 ◽  
Vol 95 (1) ◽  
pp. 24-30 ◽  
Author(s):  
Anna N.A. Tosteson ◽  
Milton C. Weinstein ◽  
Maria G.M. Hunink ◽  
Murray A. Mittleman ◽  
Lawrence W. Williams ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Serum Cholesterol ◽  
Cholesterol Levels ◽  
Reduce Serum Cholesterol

Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels

Circulation ◽  
1995 ◽  
Vol 91 (10) ◽  
pp. 2528-2540 ◽  
Author(s):  
J. Wouter Jukema ◽  
Albert V.G. Bruschke ◽  
Ad J. van Boven ◽  
Johan H.C. Reiber ◽  
Egbert T. Bal ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Serum Cholesterol ◽  
Elevated Serum ◽  
Lipid Lowering ◽  
Cholesterol Levels ◽  
Artery Disease ◽  
Elevated Serum Cholesterol

VARIATIONS IN SERUM CHOLESTEROL LEVELS AFTER MYOCARDIAL INFARCTION

1973 ◽  
Vol 1 (6) ◽  
pp. 278-282 ◽  
Author(s):  
G. R. Mundy ◽  
D. G. McPherson
Keyword(s):  
Myocardial Infarction ◽  
Serum Cholesterol ◽  
Cholesterol Levels

scholarly journals High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism?

1998 ◽  
pp. 141-145 ◽  
Author(s):  
G Michalopoulou ◽  
M Alevizaki ◽  
G Piperingos ◽  
D Mitsibounas ◽  
E Mantzos ◽  
...  
Keyword(s):  
Total Cholesterol ◽  
Serum Cholesterol ◽  
Subclinical Hypothyroidism ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
High Serum ◽  
High Serum Cholesterol ◽  
Cholesterol Levels ◽  
Group D ◽  
Tsh Levels

OBJECTIVE: The association between established hypothyroidism and high cholesterol levels is well known. The aim of the present study was to investigate the effect of thyroxine (T4) administration on cholesterol levels in hypercholesterolemic subjects with TSH levels within the normal range ('high-normal' TSH compared with 'low-normal' TSH). DESIGN AND METHODS: We determined TSH levels in 110 consecutive patients referred for hypercholesterolemia (serum cholesterol >7.5 mmol/l). Those with 'high-normal' TSH (2.0-4.0 microU/ml) as well as those with 'low-normal' TSH (0.40-1.99 microU/ml) were randomly assigned to receive either 25 or 50 microg T4 daily for two months. Thus, groups A and B (low-normal TSH) received 25 and 50 microg T4 respectively and groups C and D (high-normal TSH) received 25 and 50 microg T4 respectively. Serum T4, tri-iodothyronine (T3), TSH, free thyroxine index, resin T3 uptake and thyroid autoantibodies (ThAab) as well as total cholesterol, high and low density lipoprotein cholesterol (HDL, LDL), and triglycerides were determined before and at the end of the two-month treatment period. RESULTS: TSH levels were reduced in all groups. The most striking effect was observed in group D (TSH levels before: 2.77+/-0.55, after: 1.41+/-0.85 microU/ml, P < 0.01). Subjects in groups C and D had a higher probability of having positive ThAabs. A significant reduction in total cholesterol (P < 0.01) and LDL (P < 0.01) was observed after treatment only in group D. In those subjects in group D who were ThAab negative, there was no significant effect of thyroxine on cholesterol levels. CONCLUSIONS: Subjects with high-normal TSH levels combined with ThAabs may, in fact, have subclinical hypothyroidism presenting with elevated cholesterol levels. It is possible that these patients might benefit from thyroxine administration.

Sign in / Sign up

Export Citation Format

Share Document